Key Dates
- February 4, 2022 - Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional). See NOFO RFA-DA-22-237
National Institute on Drug Abuse (NIDA)
The NIDA intends to promote the reissue of an initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for research on Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Optional).
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The NOFO is expected to be published in Fall 2024 with an expected application due date in Spring 2025.
This NOFO will utilize the R01 activity code. Details of the planned NOFO are provided below.
This Notice encourages investigators with interest in analyzing existing data to begin to consider applying for this NOFO reissue.
Existing data provide unique opportunities to better understand interactions between intrapersonal and environmental factors and substance use and disorder (defined as tobacco, prescription, and other substance use and disorder, or these in combination with alcohol), as well as factors related to disease patterns and progressions, and variations in response to preventive interventions and substance use disorder treatment and HIV services utilization. Studies using these data might better describe, discriminate, and predict the complex, relapsing nature and course of substance use and disorder, as well as further understanding of factors predicting substance use and disorder trajectories, prevention program effects, and how services can be organized and delivered to improve enrollment, participation, retention, engagement, adherence and health outcomes. Also of special interest is the analysis of datasets that elucidate the role of substance use and its related behaviors in the evolving dynamics of HIV/AIDS pathogenesis, prevention, treatment, and service delivery including testing, treatment for HIV positive individuals, and highly active antiretroviral therapy (HAART) adherence.
Strongly encouraged is the application of innovative methods, big data analytics, computational modeling, artificial intelligence, or techniques from other disciplines that are novel to substance use and disorder research; use of multiple sources of data towards predicting substance use behaviors and solutions; or access and utilization of real-time or close to real-time data. Wherever possible, applicants should be explicit about tangible ways the findings can be translated to prevention intervention development/testing, services, policy, or other real-world impact.
Applications that include primary (new) data collection (including but not limited to interviews, surveys, focus groups, expert panel feedback, analysis of banked biospecimens) will be considered non-responsive to this NOFO and will not be reviewed.
Funding Information
NIDA intends to commit $2 million in FY 2025 for this and the companion R21 NOFO.
two-four
93.279
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government
Applications are not being solicited at this time.
Inquiries
Please direct all inquiries to:
Marsha F. Lopez, Ph.D., M.H.S.
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6504
Email: [email protected]
and Human Services (HHS)
